Stock Details
BHC is Bausch Health Companies Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 28.07$. Average daily volumn in 3 months 2.2M. Market cap 9.77B



Stock symbol : BHC. Exchange : NYSE. Currency : USD
Lastest price : 27.27$. Total volume : 2.60M. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Bausch Health Companies Inc. (BHC)
Last Price
27.27$
Change
-0.28
Volume
2.60M

Previous Close27.55
Open27.36
Day Range27.09-27.59
Bid27.00 x 800
Ask28.00 x 1.4k
Volume2.6M
Average Volume2.2M
Market Cap9.77B
Beta1.71
52 Week Range14.86-34.80
Trailing P/EN/A
Foward P/E5.73
Dividend (Yield %)N/A
Ex-Dividend Date2010-11-10



Financial Details


According to Bausch Health Companies Inc.'s financial reports the company's revenue in 2020 were 8.03B an decrease(0%) over the years 2019 revenue that were of 8.6B. In 2020 the company's total earnings were -560M while total earnings in 2019 were -1.79B(-44%).


Loading ...



Organization

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products.

Bausch Health Companies Inc._logo

Market Cap:
9.77B
Revenue:
8.03B
Total Assets:
31.2B
Total Cash:
605M


News about "Bausch Health Companies Inc."

Bausch Health Companies Inc. (NYSE: BHC): A Good Investment At Current Prices?_image

Bausch Health Companies Inc. (NYSE: BHC): A Good Investment At Current Prices?

Bausch Health Companies Inc. (NYSE:BHC)’s traded shares stood at 1.25 million during the latest session, with the company’s beta value hitting 1.69. At the last check today, the stock’s price was $27.

Source from : marketingsentinel - 1 days ago


Bausch Health Companies Inc. (BHC) distance from 20-day Simple moving Average is -3.92%: What to Expect?

Let’s start up with the current stock price of Bausch Health Companies Inc. (BHC), which is $27.55 to be very precise. The Stock rose vividly during the last session to $28.12 after opening rate of ...

Source from : investchronicle - 1 days ago


5 Healthcare Stocks to Buy According to Billionaire Mario Gabelli_image

5 Healthcare Stocks to Buy According to Billionaire Mario Gabelli

In this article, we discuss the 5 healthcare stocks to buy according to Mario Gabelli. If you want to read our detailed analysis of these stocks, go directly to the 10 Healthcare. Zoetis Inc. (NYSE: ...

Source from : Insider Monkey - 11 hours ago


Bausch Health Companies Inc. (NYSE: BHC) Shares Rose Recently, But Trouble Could Still Be Around The Corner.

Bausch Health Companies Inc. (NYSE:BHC) price closed lower on Tuesday, September 14, dropping -1.82% below its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-P ...

Source from : stocksregister - 3 days ago


Bausch Health Companies Inc. (BHC) Just Got Our Attention

Bausch Health Companies Inc. (NYSE:BHC) went down by -1.82% from its latest closing price compared to the recent 1-year high of $34.80. The company’s stock price has collected -1.95% of loss in the ...

Source from : newsheater - 3 days ago


NYSE: BHC Shareholder Notice: Investigation over Potential Wrongdoing at Bausch Health Companies Inc.

An investigation on behalf of investors in Bausch Health Companies Inc. (NYSE: BHC) shares over potential wrongdoing at Bausch Health Companies Inc. was announced. Source: Shareholders Foundation, Inc ...

Source from : SBWire - 5 days ago


DJ Bausch Health Cos. Inc. Stock Falls Thursday, Underperforms Market

Dow Jones & Company, Inc. This article was automatically generated by MarketWatch using technology from Automated Insights.

Source from : Sharecast - 2 days ago


Investigation for Investors in shares of Bausch Health Companies Inc. (NYSE: BHC) announced over potential Wrongdoing by certain directors

Certain directors of Bausch Health Companies Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Bausch Health Companies Inc. (NYSE ...

Source from : openpr.com - 8 days ago


Bausch Health Companies Inc BHC

While Bausch Health’s second-quarter results were slightly ... considering the one-time impact from the divestiture of Egyptian pharmaceutical company Amoun, which will reduce sales by $120 ...

Source from : Morningstar%2c Inc. - 5 days ago


Bausch to pay $300 mln in antitrust suit over diabetes drug_image

Bausch to pay $300 mln in antitrust suit over diabetes drug

Bausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly 800% price ...

Source from : Reuters on MSN.com - 9 days ago


Bausch Health files confidentially for IPOs of eye care business and medical aesthetics business

Inc. said Monday it has filed confidentially for the initial public offerings of its eye health business Bausch & Lomb, and its medical aesthetics business Global Solta. The company has not yet ...

Source from : Business Insider - 4 days ago


Bausch Health Companies Inc.: Bausch Buoyed by Rebounding Eyecare Despite Delta-Variant Risk, B+L Spin Likely a Year Away

Formerly known as Valeant Pharmaceuticals, Bausch Health ... Morningstar, Inc. He contributes primarily to the research coverage of South American banks and Canadian insurance companies and ...

Source from : Yahoo Finance - 10 days ago


Anaqua Delivers Enhanced IP Management to Bausch Health

Anaqua’s AQX platform to provide patent and trademark management with integrated IP analyticsBOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Anaqua, the leading innovation and intellectual property ...

Source from : YAHOO!Finance - 4 days ago


November 2022 Options Now Available For Bausch Health Companies

Investors in Bausch Health Companies Inc (Symbol: BHC) saw new options begin trading today, for the November 2022 expiration. One of the key inputs that goes into the price an option buyer is ...

Source from : Nasdaq - 11 days ago


Notable Two Hundred Day Moving Average Cross - BHC

In trading on Wednesday, shares of Bausch Health Companies Inc (Symbol: BHC) crossed below their 200 day moving average of $28.30, changing hands as low as $28.17 per share. Bausch Health ...

Source from : Nasdaq - 3 days ago


Anaqua Delivers Enhanced IP Management to Bausch Health

14, 2021, the leading innovation and intellectual property management technology provider, today announced that Bausch Health Companies Inc. has selected Anaqua's AQX platform to deliver enhanced ...

Source from : Finanznachrichten - 4 days ago


Bausch to pay $300 million in antitrust suit over diabetes drug

(Reuters) - Bausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a ...

Source from : Yahoo - 9 days ago


Bausch to pay $300 million in antitrust suit over diabetes drug

(Reuters) – Bausch Health Companies Inc (BHC.TO) has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a ...

Source from : PharmaLive - 10 days ago


Anaqua Delivers Enhanced IP Management to Bausch Health

14, 2021 (GLOBE NEWSWIRE) -- Anaqua, the leading innovation and intellectual property management technology provider, today announced that Bausch Health Companies Inc. has selected Anaqua’s AQX ...

Source from : EFE - 4 days ago


Bausch to pay $300 million in antitrust suit over diabetes drug

(Reuters) - Bausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a nearly ...

Source from : Yahoo News - 9 days ago


Bausch to pay $300 mln in antitrust suit over diabetes drug

Sept 9 (Reuters) - Bausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza ...

Source from : Yahoo - 9 days ago


Anaqua Delivers Enhanced IP Management to Bausch Health

BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Anaqua, the leading innovation and intellectual property management technology provider, today announced that Bausch Health Companies Inc. has selected ...

Source from : Yahoo Finance - 4 days ago


Intraocular Lens Market Strategic Assessment, Growth Analysis and Research Outlook 2021-2026| Novartis AG (Alcon), Bausch Health Companies Inc

Top Companies like Novartis AG (Alcon), Bausch Health Companies Inc. (Bausch + Lomb), Carl Zeiss Meditec AG, EyeKon Medical Inc., HOYA CORPORATION, HumanOptics AG, Johnson and Johnson Vision Care ...

Source from : openpr.com - 9 days ago


Canada's Bausch to pay $300 mil­lion in an­titrust set­tle­ment; Cardiff re­leas­es da­ta on mCRC tri­al_image

Canada's Bausch to pay $300 mil­lion in an­titrust set­tle­ment; Cardiff re­leas­es da­ta on mCRC tri­al

Canadian pharma company Bausch Health has agreed to settle an antitrust class-action suit from a 2015 price increase. According to Reuters, the class-action lawsuit accused Bausch of maintaining an ...

Source from : ENDPOINTS NEWS - 8 days ago


Bausch to pay $300 mln in antitrust suit over diabetes drug

Sept 9 (Reuters) - Bausch Health Companies Inc has agreed to pay $300 million to settle an antitrust lawsuit accusing it of illegally maintaining a monopoly on the diabetes drug Glumetza, enabling a ...

Source from : Yahoo Canada Sports - 9 days ago


Why Impel NeuroPharma Stock Blasted 27% Higher Thursday

After three consecutive days of declines that saw its shares crater from nearly $34 per share to less than half that figure, Impel NeuroPharma (NASDAQ:IMPL) rocketed more than 27% higher on Thursday.

Source from : The Motley Fool - 9 days ago


Bausch Health Companies Inc. (NYSE:BHC) Is Expected To Breakeven In The Near Future

Bausch Health Companies Inc. (NYSE:BHC) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Bausch Health Companies Inc. develops, ...

Source from : Yahoo News - 1 month ago


Bausch Health Companies Inc. Bond

Disclaimer | Accessibility Statement | Commerce Policy | Made In NYC | Stock quotes by finanzen.net More Bonds of Bausch Health Companies Inc. Add instrument to watchlist Bond Data About the ...

Source from : Business Insider - 11 days ago


Bausch Health Cos. Inc.

1 Day BHC 3.02% DJIA 0.69% S&P 500 0.88% Health Care/Life Sciences -0.49% Joseph C. Papa Chairman & Chief Executive Officer Prometheus Biosciences, Inc, Bausch Health Cos., Inc. Brett M.

Source from : Wall Street Journal - 23 days ago


Activist Spotlight: Activists In Bausch Health With Catalysts On Horizon

Comparables like Cooper Companies and Alcon Inc. are currently trading between ... the total value of Bausch Health using sum-of-the-parts method, net of debt, should be worth north of $35 per ...

Source from : Seeking Alpha - 17 days ago


Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

LAVAL, QC, Sept. 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals ...

Source from : PR Newswire - 16 days ago


Bausch Health Cos. Inc.

1 Day BHC 2.50% DJIA 0.69% S&P 500 0.88% Health Care/Life Sciences -0.35% Joseph C. Papa Chairman & Chief Executive Officer Prometheus Biosciences, Inc, Bausch Health Cos., Inc. Brett M.

Source from : Wall Street Journal - 22 days ago